Great to see evidence over two seasons showing the profound positive impact of nirsevimab on RSV hospitalizations in infants. Hospitalizations were reduced by 86% for season 1 and 55% in season 2 in Spain.
RFK.Jr's FDA is trying to ban this therapy in the US!
www.thelancet.com/journals/lan...
RFK.Jr's FDA is trying to ban this therapy in the US!
www.thelancet.com/journals/lan...
Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective...
Universal infant nirsevimab prophylaxis markedly reduced RSV-related hospitalisations
and outpatient morbidity, with sustained reductions in RSV-related LRTI hospitalisations
into the second season an...
www.thelancet.com
January 14, 2026 at 1:23 PM
Great to see evidence over two seasons showing the profound positive impact of nirsevimab on RSV hospitalizations in infants. Hospitalizations were reduced by 86% for season 1 and 55% in season 2 in Spain.
RFK.Jr's FDA is trying to ban this therapy in the US!
www.thelancet.com/journals/lan...
RFK.Jr's FDA is trying to ban this therapy in the US!
www.thelancet.com/journals/lan...
#Medsky🧪 #IDsky #pedsky #publichealth This full RSV season analysis confirms that #nirsevimab reduced infant hospitalisation for #RSV-related LRTI, RSV-related LRTI requiring oxygen, and all-cause #bronchiolitis or #bronchitis,
www.thelancet.com/journals/lan...
www.thelancet.com/journals/lan...
Full 2023–24 season results of universal prophylaxis with nirsevimab in Galicia, Spain: the NIRSE-GAL study
In April, 2024, we reported on mid-season findings from NIRSE-GAL, a population-based longitudinal study on the effectiveness of universal nirsevimab prophylaxis against respiratory syncytial virus (RSV) in infants aged 0–24 months in Galicia, Spain.1 Our early findings aligned with other interim real-world studies on the considerable effectiveness of nirsevimab in preventing RSV-related hospitalisations for lower respiratory tract infections (LRTIs).2 The immunisation campaign in Galicia (which ran from Sept 25, 2023, to March 31, 2024) is described elsewhere.
www.thelancet.com
December 12, 2024 at 8:00 AM
#Medsky🧪 #IDsky #pedsky #publichealth This full RSV season analysis confirms that #nirsevimab reduced infant hospitalisation for #RSV-related LRTI, RSV-related LRTI requiring oxygen, and all-cause #bronchiolitis or #bronchitis,
www.thelancet.com/journals/lan...
www.thelancet.com/journals/lan...
Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective observational study - The Lancet Infectious Diseases www.thelancet.com/journals/lan...
Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective...
Universal infant nirsevimab prophylaxis markedly reduced RSV-related hospitalisations
and outpatient morbidity, with sustained reductions in RSV-related LRTI hospitalisations
into the second season an...
www.thelancet.com
April 23, 2026 at 10:51 PM
Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective observational study - The Lancet Infectious Diseases www.thelancet.com/journals/lan...
The NIRSE-GAL study looking at real world impact of nirsevimab in infants in Spain.
Of 12 492 eligible infants, 94·4% received immunization. RSV-related LRTI hospitalisations decreased by 85·9% in the 1st season and 55·3% in the 2nd.
www.thelancet.com/journals/lan... #IDSky
Of 12 492 eligible infants, 94·4% received immunization. RSV-related LRTI hospitalisations decreased by 85·9% in the 1st season and 55·3% in the 2nd.
www.thelancet.com/journals/lan... #IDSky
Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective...
Universal infant nirsevimab prophylaxis markedly reduced RSV-related hospitalisations
and outpatient morbidity, with sustained reductions in RSV-related LRTI hospitalisations
into the second season an...
www.thelancet.com
January 13, 2026 at 2:07 PM
The NIRSE-GAL study looking at real world impact of nirsevimab in infants in Spain.
Of 12 492 eligible infants, 94·4% received immunization. RSV-related LRTI hospitalisations decreased by 85·9% in the 1st season and 55·3% in the 2nd.
www.thelancet.com/journals/lan... #IDSky
Of 12 492 eligible infants, 94·4% received immunization. RSV-related LRTI hospitalisations decreased by 85·9% in the 1st season and 55·3% in the 2nd.
www.thelancet.com/journals/lan... #IDSky
1) 2024 termina hoy dejándonos uno de los estudios de > impacto en prevención con #Nirsevimab contra #VRS Virus Respiratorio Sincitial, el estudio #Nirse-Gal via #lancetid y liderado por Federico Martinon-Torres y cols. Impacto fantástico. #stoprsv #pedsky #idsky #pedsidsky
doi.org/10.1016/S147...
doi.org/10.1016/S147...
Redirecting
doi.org
December 31, 2024 at 7:17 PM
1) 2024 termina hoy dejándonos uno de los estudios de > impacto en prevención con #Nirsevimab contra #VRS Virus Respiratorio Sincitial, el estudio #Nirse-Gal via #lancetid y liderado por Federico Martinon-Torres y cols. Impacto fantástico. #stoprsv #pedsky #idsky #pedsidsky
doi.org/10.1016/S147...
doi.org/10.1016/S147...
The new paper tracked almost 12.5 thousand infants during the 2023–24 and 24-25 RSV seasons given the monoclonal. Over 94% were vaccinated. Hospitalisations fell nearly 86% in 2023–24 and 55% in 2024–25. That is incredible data and really good news.
Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective...
Universal infant nirsevimab prophylaxis markedly reduced RSV-related hospitalisations
and outpatient morbidity, with sustained reductions in RSV-related LRTI hospitalisations
into the second season an...
www.thelancet.com
January 14, 2026 at 8:20 AM
The new paper tracked almost 12.5 thousand infants during the 2023–24 and 24-25 RSV seasons given the monoclonal. Over 94% were vaccinated. Hospitalisations fell nearly 86% in 2023–24 and 55% in 2024–25. That is incredible data and really good news.
New Research
Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective observational study
www.thelancet.com/journals/lan...
Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective observational study
www.thelancet.com/journals/lan...
Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective...
Universal infant nirsevimab prophylaxis markedly reduced RSV-related hospitalisations
and outpatient morbidity, with sustained reductions in RSV-related LRTI hospitalisations
into the second season an...
www.thelancet.com
January 13, 2026 at 8:12 AM
New Research
Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective observational study
www.thelancet.com/journals/lan...
Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective observational study
www.thelancet.com/journals/lan...
🔷 L'étude NIRSE-GAL publiée dans The Lancet Infectious Diseases ce 16 février 2026, concerne l'immunisation par le Beyfortus (nirsevimab) contre le virus respiratoire syncytial des nourrissons.
March 4, 2026 at 6:41 AM
🔷 L'étude NIRSE-GAL publiée dans The Lancet Infectious Diseases ce 16 février 2026, concerne l'immunisation par le Beyfortus (nirsevimab) contre le virus respiratoire syncytial des nourrissons.
🚨 Breaking: Full 2023-24 results from the NIRSE-GAL study in Galicia, Spain, confirm effectiveness of universal nirsevimab prophylaxis in preventing RSV-related hospitalizations in infants. 📖 Published at Lancet Infectious Diseases www.thelancet.com/callback?red...
Lancet
www.thelancet.com
January 18, 2025 at 11:37 PM
🚨 Breaking: Full 2023-24 results from the NIRSE-GAL study in Galicia, Spain, confirm effectiveness of universal nirsevimab prophylaxis in preventing RSV-related hospitalizations in infants. 📖 Published at Lancet Infectious Diseases www.thelancet.com/callback?red...
97.5% of babies were given nirsevimab (Beyfortus), which is the monoclonal antibody that protects against severe RSV. This was very successful start. More details about progress here: www.nirsegal.es/en
2/2
2/2
Nirse-gal study: evolution of Immunization Coverage with Nirsevimab
The Nirse-gal study shows the evolution of the coverage outcome achieved by immunization with Nirsevimab and the admissions due to RSV (Respiratory Syncytial Virus) in different population groups of children and adults in the province of Galicia in Spain.
www.nirsegal.es
December 9, 2023 at 3:23 PM
97.5% of babies were given nirsevimab (Beyfortus), which is the monoclonal antibody that protects against severe RSV. This was very successful start. More details about progress here: www.nirsegal.es/en
2/2
2/2
Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective observational study
Nirsevimab en la vida real: 5 hallazgos de Galicia que cambian el juego para…
Nirsevimab en la vida real: 5 hallazgos de Galicia que cambian el juego para…
Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective observational study
Nirsevimab en la vida real: 5 hallazgos de Galicia que cambian el juego para la pediatría de atención primaria Como pediatras, conocemos bien el "estrés del sistema" que cada invierno satura nuestras consultas. Las salas de espera desbordadas por lactantes con sibilancias y la angustia de las familias ante la bronquiolitis por virus respiratorio sincitial (VRS) han sido, hasta ahora, una constante inevitable.
gpiaepap.wordpress.com
July 15, 2026 at 6:21 PM
Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective observational study
Nirsevimab en la vida real: 5 hallazgos de Galicia que cambian el juego para…
Nirsevimab en la vida real: 5 hallazgos de Galicia que cambian el juego para…
2) #Nirsevimab contributed to reducing RSV-related
LRTI hospitalisations in Galicia by a median of 89·2% (IQR 89·1–91·4) in the overall cohort and by 95·2% (94·8–96·2) in the seasonal cohort.(..)" Grandes avances contra VRS/RSV. #stoprsv #pedsky #idsky #pedsidsky
www.thelancet.com/journals/lan...
LRTI hospitalisations in Galicia by a median of 89·2% (IQR 89·1–91·4) in the overall cohort and by 95·2% (94·8–96·2) in the seasonal cohort.(..)" Grandes avances contra VRS/RSV. #stoprsv #pedsky #idsky #pedsidsky
www.thelancet.com/journals/lan...
Full 2023–24 season results of universal prophylaxis with nirsevimab in Galicia, Spain: the NIRSE-GAL study
In April, 2024, we reported on mid-season findings from NIRSE-GAL, a population-based longitudinal study on the effectiveness of universal nirsevimab prophylaxis against respiratory syncytial virus (RSV) in infants aged 0–24 months in Galicia, Spain.1 Our early findings aligned with other interim real-world studies on the considerable effectiveness of nirsevimab in preventing RSV-related hospitalisations for lower respiratory tract infections (LRTIs).2 The immunisation campaign in Galicia (which ran from Sept 25, 2023, to March 31, 2024) is described elsewhere.
www.thelancet.com
December 31, 2024 at 7:17 PM
2) #Nirsevimab contributed to reducing RSV-related
LRTI hospitalisations in Galicia by a median of 89·2% (IQR 89·1–91·4) in the overall cohort and by 95·2% (94·8–96·2) in the seasonal cohort.(..)" Grandes avances contra VRS/RSV. #stoprsv #pedsky #idsky #pedsidsky
www.thelancet.com/journals/lan...
LRTI hospitalisations in Galicia by a median of 89·2% (IQR 89·1–91·4) in the overall cohort and by 95·2% (94·8–96·2) in the seasonal cohort.(..)" Grandes avances contra VRS/RSV. #stoprsv #pedsky #idsky #pedsidsky
www.thelancet.com/journals/lan...
- #Nirsevimab use in the 2023-24 season led to a significant reduction in RSV #bronchiolitis cases in both hospital & ambulatory settings, even with different RSV strains predominating.
- A study in Galicia, 🇪🇸(NIRSE-GAL) found that the benefits of nirsevimab extended beyond 1st year,
- A study in Galicia, 🇪🇸(NIRSE-GAL) found that the benefits of nirsevimab extended beyond 1st year,
January 14, 2026 at 1:01 AM
- #Nirsevimab use in the 2023-24 season led to a significant reduction in RSV #bronchiolitis cases in both hospital & ambulatory settings, even with different RSV strains predominating.
- A study in Galicia, 🇪🇸(NIRSE-GAL) found that the benefits of nirsevimab extended beyond 1st year,
- A study in Galicia, 🇪🇸(NIRSE-GAL) found that the benefits of nirsevimab extended beyond 1st year,
Aval a la inmunización con nirsevimab: reduce un 90% las hospitalizaciones por el virus
www.diariomedico.com/medicina/ped...
www.diariomedico.com/medicina/ped...
Aval a la inmunización con nirsevimab: reduce un 90% las hospitalizaciones por el virus
Un estudio del grupo Nirse-GAL muestra que la profilaxis universal en bebés con nirsevimab frente al VRS es una medida de salud pública segura y efectiva.
www.diariomedico.com
December 27, 2024 at 4:30 PM
Aval a la inmunización con nirsevimab: reduce un 90% las hospitalizaciones por el virus
www.diariomedico.com/medicina/ped...
www.diariomedico.com/medicina/ped...